The expression of SOCS1 and TLR4-NFκB pathway molecules in neoplastic cells as potential biomarker for the aggressive tumor phenotype in laryngeal carcinoma

Folia Histochemica et Cytobiologica

Volumn 47, Issue 3, 2009, Pages 401-410

  Starska, Katarzyna ^a   Forma, Ewa ^b   Lewy Trenda, Iwona ^a   Stasikowska, Olga ^a   Bryś, Magdalena ^b   Krajewska, Wanda M ^b   Łukomski, Marek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

IRAK1 (interleukin 1 receptor Associated kinase); Laryngeal carcinoma; NF B (nuclear factor kappa B; p65 subunit); SOCS1 (suppressor of cytokine signaling 1); TFG (tumor front grading); TLR4 (toll like receptor 4); TRAF6 (TNF receptor associated factor 6)

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MESSENGER RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; CLINICAL ARTICLE; CORRELATION ANALYSIS; EPITHELIUM CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MALE; MITOSIS; PATHOLOGY; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL;

EID: 77149164456     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-009-0075-2     Document Type: Article

References (41)

1. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther. 2005; 7(3):100-110.
2. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol. 2004; 22:503-529.
3. Gingras S, Parganas E, de Pauw A, Ihle JN, Murray PJ. Reexamination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of toll-like receptor signaling. J Biol Chem. 2004;279(52):54702-54707.
4. Baetz A, Frey M, Heeg K, Dalpke AH. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J Biol Chem. 2004;279(52):54708-54715.
5. Kimura A, Naka T, Muta T, Takeuchi O, Akira S, Kawase I et al. Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT. Proc Natl Acad Sci USA. 2005;102(47):17089-17094.
6. Yoshimura A, Ohishi HM, Aki D, Hanada T. Regulation of TLR signaling and inflammation by SOCS family proteins. J Leukoc Biol. 2004; 75(3):422-427.
7. Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, Crack PJ et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol. 2006; 7(2):148-155.
8. Mansell A, Brint E, Gould JA, O'Neill LA, Hertzog PJ. Mal interacts with tumor necrosis factor receptor-associated factor (TRAF)-6 to mediate NF-kappaB activation by toll-like receptor (TLR)-2 and TLR4. J Biol Chem. 2004;279(36): 37227-37230.
9. Haffner MC, Petridou B, Peyrat JP, Révillion F, Müller-Holzner E, Daxenbichler G et al. Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer. 2007; 7:136.
10. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene. 2005; 24(44):6699-6708.
11. Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH et al. The tumor suppressor activity of SOCS-1. Oncogene. 2002; 21(28):4351-4362.
12. Hertzog PJ, O'Neill LA, Hamilton JA. The interferon in TLR signaling: more than just antiviral. Trends Immunol. 2003; 24(10):534-539.
13. John Wiley & Sons. TNM Classification of Malignant Tumours. 6th edition Hoboken: New Jersey; 2002.
14. Welkoborsky HJ, Hinni M, Dienes HP, Mann WJ. Predicting reccurence and survival in patients with laryngeal cancer by means of DNA cytometry, tumor front grading and proliferation markers. Ann Otol Rhinol Laryngol 1995; 104: 503-511.
15. Yoshimura A. Negative regulation of cytokine signaling. Clin Rev Allergy Immunol. 2005; 28(3):205-20.
16. Evans MK, Yu CR, Lohani A, Mahdi RM, Liu X, Trzeciak AR et al. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene. 2007; 26(13):1941-1948.
17. Lebrun P, Van Obberghen E. SOCS proteins causing trouble in insulin action. Acta Physiol (Oxf). 2008; 192(1):29-36.
18. Liu E, Côté JF, Vuori K. Negative regulation of FAK signaling by SOCS proteins. EMBO J. 2003; 22(19):5036-5046.
19. De Sepulveda P, Ilangumaran S, Rottapel R. Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J Biol Chem. 2000; 275(19):14005-14008.
20. Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem. 2007; 100(5):1301-1312.
21. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007; 13(11):460-469.
22. Fraczek J, Kim TW, Xiao H, Yao J, Wen Q, Li Y et al. The kinase activity of IL-1 receptor-associated kinase 4 is required for interleukin-1 receptor/toll-like receptor-induced TAK1-dependent NFkappaB activation. J Biol Chem. 2008; 283(46):31697-31705.
23. Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W et al. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene. 2004; 23(46):7726-7733.
24. Prele CM, Woodward EA, Bisley J, Keith-Magee A, Nicholson SE, Hart PH. SOCS1 regulates the IFN but not NFkappaB pathway in TLR-stimulated human monocytes and macrophages. J Immunol. 2008; 181(11):8018-8026.
25. Gingras S, Parganas E, de Pauw A, Ihle JN, Murray PJ. Reexamination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of toll-like receptor signaling. J Biol Chem. 2004; 279(52):54702-54707.
26. Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, Chai RL, Ferrell RE et al. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst. 2006; 98(3):181-189.
27. Okamoto M, Oshikawa T, Tano T, Ohe G, Furuichi S, Nishikawa H et al. Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst. 2003; 95(4):316-326.
28. Szczepanski M, Stelmachowska M, Stryczynski L, Golusinski W, Samara H, Mozer-Lisewska I et al. Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol. 2007; 264:525-530.
29. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, Gutkind JS. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia. 2006; 8:733-746.
30. Huang B, Zhao J, Shen S, Li H, He KL, Shen GX et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res. 2007; 67:4346-4352.
31. Frenzel H, Hoffmann B, Brocks C, Schlenke P, Pries R, Wollenberg B. Toll-like receptor interference in myeloid dendritic cells through head and neck cancer. Anticancer Res. 2006; 26:4409-4413.
32. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007; 2004:1441-1451.
33. Simiantonaki N, Kurzik-Dumke U, Karyofylli G, Jayasinghe C, Michel-Schmidt R, Kirkpatrick CJ. Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer. Int J Mol Med. 2007; 20(1):21-29.
34. Ohara T, Morishita T, Suzuki H, Hibi T. Heterozygous Thr 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas. Int J Mol Med. 2006; 18(1):59-63.
35. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009; 69(7):3105-13.
36. Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A. The transcription factor nuclear factor-kappa B and cancer. Clin Oncol. 2007; 19(2):154-161.
37. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol. 2007; 22(12):1387-1398.
38. Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R et al. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer. 2008; 8:41.
39. Jin X, Wang Z, Qiu L, Zhang D, Guo Z, Gao Z et al. Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer. Cancer Sci. 2008; 99(3):582-589.
40. Kourelis K, Sotiropoulou-Bonikou G, Vandoros G, Repanti M, Varakis I, Goumas P. Coordinated upregulation of COX-2 and NF-kappaB is a steady feature of laryngeal carcinogenesis. ORL J Otorhinolaryngol Relat Spec. 2007;69(3):181-9.
41. Starska K, Kulig A, Lukomski M. Tumor front grading in prediction of survival and lymph node metastases in patients with laryngeal carcinoma. Adv Med Sci. 2006; 51:200-204.